Clinical Trials · NCT06252623
Exenatide For Reducing the Reinforcing Effects of Cocaine
- Phase
- Phase 1
- Recruitment status
- Withdrawn
- Sponsor
- Christopher D. Verrico
- Enrollment
- 0
- Start date
- Aug 2024
- Locations
- 1 site, United States
- Primary endpoint
- Proportion of up to 10 active cocaine doses